Tonix's lead drug fails PhIII again, sending stock even closer to zero
When little Tonix Pharmaceuticals revealed last July that its lead drug failed an interim analysis in fibromyalgia — so much so that outside data monitors recommended halting the trial it would unlikely pass muster — the company decided to go ahead and follow patients already on the drug.
So it’s little surprise that TNX-102 flat out failed the final analysis of the Phase III RALLY study too, missing statistical significance over placebo on the primary endpoint of reduction in daily pain.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.